Држава: Канада
Језик: Енглески
Извор: Health Canada
NAPROXEN SODIUM
TEVA CANADA LIMITED
M01AE02
NAPROXEN
550MG
TABLET
NAPROXEN SODIUM 550MG
ORAL
100/500
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0113934002; AHFS:
APPROVED
2010-07-06
TEVA-NAPROXEN SODIUM / TEVA-NAPROXEN SODIUM DS Page 1 of 44 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-NAPROXEN SODIUM PR TEVA-NAPROXEN SODIUM DS Naproxen Sodium Tablets Tablet, 275 mg and 550 mg, Oral USP ATC Code: M01AE02 Non-Steroidal Anti-Inflammatory Drug (NSAID) Teva Canada Limited 30 Novopharm Court Toronto, Ontario, Canada M1B 2K9 Date of Initial Authorization: July 19, 2010 Date of Revision: July 18, 2022 Submission Control No: 260925 TEVA-NAPROXEN SODIUM / TEVA-NAPROXEN SODIUM DS Page 2 of 44 RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 07/2022 3 SERIOUS WARNING AND PRECAUTIONS BOX 07/2022 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests, Pregnancy 07/2022 7 WARNINGS AND PRECAUTIONS, Psychiatric 07/2022 7 WARNINGS AND PRECAUTIONS, Skin 07/2022 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 07/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES……………………………………………………………………………………………2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION....................................................................... 4 1 INDICATIONS ........................................................................................................................ 4 1.1 Pediatrics ....................................................................................................................... 4 1.2 Geriatrics ....................................................................................................................... 4 2 CONTRAINDICATIONS........................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................................... 6 4 DOSAGE AND ADMINISTRATION .......................................................................................... 7 4.1 Dosing considerations................. Прочитајте комплетан документ